title: Stones: Tolvaptan might prevent kidney stone formation.
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, UMR S 702, F-75020, Paris, France; INSERM, UMR S 1155, F-75020, Paris, France; and the Physiology Unit, AP-HP, Hôpital Tenon, F-75020, Paris, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Letavernier
authors.affiliation: Sorbonne Universités, UPMC Univ Paris 06, UMR S 702, F-75020, Paris, France; INSERM, UMR S 1155, F-75020, Paris, France; and the Physiology Unit, AP-HP, Hôpital Tenon, F-75020, Paris, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Daudon
mesh_terms: D006801:Humans; D007669:Kidney Calculi
references.citation: Drug Saf. 2015 Nov;38(11):1103-13
references.pmid: 26188764
references.citation: J Urol. 2007 Jun;177(6):2227-9; discussion 2230
references.pmid: 17509326
references.citation: J Urol. 2016 May;195(5):1476-81
references.pmid: 26598423
references.citation: Ann Intern Med. 2012 Sep 18;157(6):459-60
references.pmid: 22986392
references.citation: Miner Electrolyte Metab. 1982 Apr;7(4):192-6
references.pmid: 7169985
references.citation: Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18644-9
references.pmid: 24167258
references.citation: Physiol Rep. 2015 Nov;3(11):null
references.pmid: 26620256
references.citation: J Urol. 1996 Mar;155(3):839-43
references.pmid: 8583588